Chloroquine

Generic Name
Chloroquine
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C18H26ClN3
CAS Number
54-05-7
Unique Ingredient Identifier
886U3H6UFF
Background

Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as pyrimethamine, artemisinin, and mefloquine. Chloroquine and its derivative hydroxychloroquine have since been repurposed for the treatment of a number of other c...

Indication

Chloroquine is indicated to treat infections of P. vivax, P. malariae, P. ovale, and susceptible strains of P. falciparum. It is also used to treat extraintestinal amebiasis.
...

Associated Conditions
Discoid Lupus Erythematosus (DLE), Extraintestinal Amebiasis, Malaria, Polymorphic Light Eruption (PLE), Porphyria Cutanea Tarda, Rheumatoid Arthritis, Sarcoidosis, Acute, uncomplicated Malaria
Associated Therapies
-

Chloroquine and Post Malaria Anaemia Study

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2007-05-16
Last Posted Date
2014-10-13
Lead Sponsor
Medical Research Council Unit, The Gambia
Target Recruit Count
96
Registration Number
NCT00473837

Atheroma Reduction With Chloroquine in Patients With the Metabolic Syndrome (ARCH-MS)

First Posted Date
2007-04-03
Last Posted Date
2021-12-15
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
357
Registration Number
NCT00455403
Locations
🇺🇸

Washington University School of Medicine, Saint Louis, Missouri, United States

Safety and Efficacy of Chloroquine Associated With Dehydroepiandrosterone Sulphate to Treat Uncomplicated Falciparum Malaria

Phase 3
Suspended
Conditions
First Posted Date
2007-03-01
Last Posted Date
2007-03-01
Lead Sponsor
Université Victor Segalen Bordeaux 2
Target Recruit Count
200
Registration Number
NCT00442403
Locations
🇨🇲

Institute of Medical Research and study of Medicinal Plants, Medical Research Center, Yaounde, Cameroon

Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria

Phase 3
Completed
Conditions
Interventions
First Posted Date
2007-02-27
Last Posted Date
2021-11-02
Lead Sponsor
Medicines for Malaria Venture
Target Recruit Count
456
Registration Number
NCT00440999
Locations
🇹🇭

MaeLamad District Hospital, Mae Ramat, Tak Province, Thailand

🇹🇭

MaeSod General Hospital, Mae Sot, Tak Province, Thailand

🇰🇭

Pailin Referral Hospital, Pailin, Pailin Province, Cambodia

and more 2 locations

Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau

First Posted Date
2007-01-24
Last Posted Date
2011-01-04
Lead Sponsor
Bandim Health Project
Target Recruit Count
300
Registration Number
NCT00426439
Locations
🇬🇼

Bandim Health Project, Apartado 861, Bissau, Guinea-Bissau

CuraChik : A Trial of the Efficacy and Safety of Chloroquine as Therapeutic Treatment of Chikungunya Disease

Phase 3
Terminated
Conditions
First Posted Date
2006-10-23
Last Posted Date
2015-08-28
Lead Sponsor
Assistance Publique Hopitaux De Marseille
Registration Number
NCT00391313
Locations
🇫🇷

Cellule Coordination Nivachik, Saint Pierre, ile de la Reunion, France

Chloroquine Alone or in Combination for Malaria in Children in Malawi

First Posted Date
2006-09-25
Last Posted Date
2014-08-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
640
Registration Number
NCT00379821
Locations
🇲🇼

Blantyre Malaria Project - Ndirande Health Centre, Blantyre, Malawi

Investigating the Anti-Human Immunodeficiency Virus (HIV) & Anti-inflammatory Effect of Chloroquine

Phase 2
Terminated
Conditions
Interventions
First Posted Date
2006-03-29
Last Posted Date
2020-06-04
Lead Sponsor
University of Minnesota
Target Recruit Count
13
Registration Number
NCT00308620
Locations
🇺🇸

Minnesota ACTU, Minneapolis, Minnesota, United States

Chloroquine for Treatment of Glioblastoma Multiforme

Phase 3
Completed
Conditions
First Posted Date
2005-09-23
Last Posted Date
2009-11-18
Lead Sponsor
National Institute of Neurology and Neurosurgery, Mexico
Registration Number
NCT00224978
Locations
🇲🇽

National Institute of Neurology and Neurosurgery, Mexico City, Mexico

Impact of Insecticide-treated Curtains on Antimalarial Drug Resistance

Not Applicable
Completed
Conditions
First Posted Date
2005-09-15
Last Posted Date
2017-01-12
Lead Sponsor
London School of Hygiene and Tropical Medicine
Target Recruit Count
1035
Registration Number
NCT00169078
Locations
🇧🇫

Centre National de Recherche et de Formation sur le Paludisme, Ouagadougou, Kadiogo, Burkina Faso

© Copyright 2024. All Rights Reserved by MedPath